Biotech entity
pharma is the sole category represented across all 1 tracked stories. Nuplazid is most often covered alongside Acadia Pharmaceuticals, which appears in 1 of these 1 story. The tracked stories average 2 original sources each. Nuplazid appears in 1 tracked Biotech story from February 27, 2026.
Last mentioned: Feb 27, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Nuplazid is most often covered alongside Acadia Pharmaceuticals, which appears in 1 of these 1 story. The tracked stories average 2 original sources each. Nuplazid appears in 1 tracked Biotech story from February 27, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 17 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Nuplazid. Shared-story counts are live from our verified record — not editorial picks.
Q4 Earnings Call
ACADIA reports strong year-end results and 2026 guidance.
Daybue Stix Launch
Launch of the granule formulation to enhance patient compliance.
Daybue Approval
FDA approves Daybue as the first treatment for Rett syndrome.
Nuplazid Approval
FDA approves Nuplazid for Parkinson's disease psychosis.
ACADIA Pharmaceuticals delivered a strong Q4 performance, underscored by the rapid adoption of Daybue and the resilience of its Parkinson’s franchise. The results highlight a successful transition into a diversified commercial-stage biotech with a clear path to sustained profitability.
Nuplazid is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
